Wellgistics Health (WGRX)
Market Price (7/21/2026): $3.39 | Market Cap: $7.1 MilSector: Consumer Staples | Industry: Drug Retail
Wellgistics Health (WGRX)
Market Price (7/21/2026): $3.39Market Cap: $7.1 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76% | Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -164% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -398% Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 509% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -52%, Rev Chg QQuarterly Revenue Change % is -86% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 202% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -92%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -98% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1355% High stock price volatilityVol 12M is 265% Key risksWGRX key risks include [1] poor financial health and high leverage that raise substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for failing to meet the minimum bid price requirement. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -76% |
| Weak multi-year price returns2Y Excs Rtn is -131%, 3Y Excs Rtn is -164% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -56 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -398% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 509% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -52%, Rev Chg QQuarterly Revenue Change % is -86% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 202% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -92%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -98% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1355% |
| High stock price volatilityVol 12M is 265% |
| Key risksWGRX key risks include [1] poor financial health and high leverage that raise substantial doubt about its ability to continue as a going concern and [2] a potential delisting from Nasdaq for failing to meet the minimum bid price requirement. |
Qualitative Assessment
AI Analysis | Feedback
Wellgistics Health (WGRX) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Operating Losses and Negative Financial Performance. Wellgistics Health reported a net operating loss of $7.742 million for fiscal Q1 2026, which ended March 31, 2026, despite a reduction from the $32.430 million loss in fiscal Q1 2025. For the full fiscal year 2025, the company posted a staggering net loss of -$101.3 million. The company's price-to-earnings (P/E) ratio remains negative at -0.06, indicating a lack of profitability. These recurring losses and negative financial indicators have contributed to investor skepticism regarding the company's long-term viability and growth prospects.
2. Reverse Stock Split and Continued Nasdaq Compliance Challenges. Wellgistics Health executed a 1-for-50 reverse stock split, effective May 26, 2026, primarily to raise its share price and regain compliance with Nasdaq's minimum bid price requirement. Despite this action, the stock has continued its downward trend, decreasing 55.9% since its Q1 2026 earnings release on May 19, 2026, and experiencing a 59.64% decline in the past month alone. This suggests that the reverse split did not instill lasting investor confidence and highlights ongoing concerns about the company's ability to maintain its Nasdaq listing.
Show more
Wellgistics Health (WGRX) stock has lost about 45% since 3/31/2026 because of the following key factors:
1. Persistent Operating Losses and Negative Financial Performance. Wellgistics Health reported a net operating loss of $7.742 million for fiscal Q1 2026, which ended March 31, 2026, despite a reduction from the $32.430 million loss in fiscal Q1 2025. For the full fiscal year 2025, the company posted a staggering net loss of -$101.3 million. The company's price-to-earnings (P/E) ratio remains negative at -0.06, indicating a lack of profitability. These recurring losses and negative financial indicators have contributed to investor skepticism regarding the company's long-term viability and growth prospects.
2. Reverse Stock Split and Continued Nasdaq Compliance Challenges. Wellgistics Health executed a 1-for-50 reverse stock split, effective May 26, 2026, primarily to raise its share price and regain compliance with Nasdaq's minimum bid price requirement. Despite this action, the stock has continued its downward trend, decreasing 55.9% since its Q1 2026 earnings release on May 19, 2026, and experiencing a 59.64% decline in the past month alone. This suggests that the reverse split did not instill lasting investor confidence and highlights ongoing concerns about the company's ability to maintain its Nasdaq listing.
3. Shareholder Dilution Concerns and High Short Interest. While Wellgistics Health terminated a dilutive Section 3(a)(10) Settlement Agreement with Silverback Capital on April 3, 2026, to curb future share issuances, the company has experienced substantial shareholder dilution over the past year, with total shares outstanding growing by 103.6%. This dilution, alongside a significant short interest of 5.74% of the float, which recently increased by 3.85%, reflects a prevailing negative investor sentiment and expectations of further price declines.
4. Negative Analyst Sentiment and Lack of Institutional Support. Wellgistics Health currently holds a consensus "Sell" rating based on the single available analyst research report, with an average rating score of 1.00. Furthermore, analysts have not established any price targets for the company's stock. This lack of positive analyst coverage and institutional endorsement can deter new investors and exacerbate negative pressure on the stock, particularly for a micro-cap company.
Show less
Stock Movement Drivers
Fundamental Drivers
The -43.8% change in WGRX stock from 3/31/2026 to 7/20/2026 was primarily driven by a -39.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312026 | 7202026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.82 | 2.71 | -43.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 23 | 14 | -39.9% |
| P/S Multiple | 0.4 | 0.4 | 1.3% |
| Shares Outstanding (Mil) | 2 | 2 | -7.7% |
| Cumulative Contribution | -43.8% |
Market Drivers
3/31/2026 to 7/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | -43.8% | |
| Market (SPY) | 14.1% | 1.5% |
| Sector (XLP) | 3.5% | 3.1% |
Fundamental Drivers
The -86.4% change in WGRX stock from 12/31/2025 to 7/20/2026 was primarily driven by a -58.8% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7202026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.98 | 2.71 | -86.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 14 | -58.8% |
| P/S Multiple | 0.9 | 0.4 | -53.7% |
| Shares Outstanding (Mil) | 1 | 2 | -28.9% |
| Cumulative Contribution | -86.4% |
Market Drivers
12/31/2025 to 7/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | -86.4% | |
| Market (SPY) | 9.1% | 7.1% |
| Sector (XLP) | 9.9% | 8.4% |
Fundamental Drivers
The -94.4% change in WGRX stock from 6/30/2025 to 7/20/2026 was primarily driven by a -76.7% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7202026 | Change |
|---|---|---|---|
| Stock Price ($) | 48.43 | 2.71 | -94.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 29 | 14 | -51.6% |
| P/S Multiple | 1.7 | 0.4 | -76.7% |
| Shares Outstanding (Mil) | 1 | 2 | -50.4% |
| Cumulative Contribution | -94.4% |
Market Drivers
6/30/2025 to 7/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | -94.4% | |
| Market (SPY) | 21.1% | 7.1% |
| Sector (XLP) | 7.0% | 0.6% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/20/2026| Return | Correlation | |
|---|---|---|
| WGRX | ||
| Market (SPY) | 73.3% | 9.7% |
| Sector (XLP) | 23.3% | 4.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| WGRX Return | - | - | - | - | -90% | -87% | -99% |
| Peers Return | 16% | 25% | 22% | 37% | 58% | 9% | 317% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| WGRX Win Rate | - | - | - | - | 27% | 14% | |
| Peers Win Rate | 50% | 60% | 58% | 57% | 67% | 57% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| WGRX Max Drawdown | - | - | - | - | - | -88% | |
| Peers Max Drawdown | -27% | -25% | -24% | -29% | -22% | -31% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MCK, COR, CAH, CVS, HIMS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/20/2026 (YTD)
How Low Can It Go
WGRX has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -12.2% | -9.5% |
| % Gain to Breakeven | 13.8% | 10.5% |
| Time to Breakeven | 146 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -12.1% | -24.5% |
| % Gain to Breakeven | 13.8% | 32.4% |
| Time to Breakeven | 46 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -24.2% | -33.7% |
| % Gain to Breakeven | 31.9% | 50.9% |
| Time to Breakeven | 140 days | 140 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -10.7% | -17.9% |
| % Gain to Breakeven | 12.0% | 21.8% |
| Time to Breakeven | 78 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -31.8% | -53.4% |
| % Gain to Breakeven | 46.7% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street Consumer Staples Select Sector SPDR ETF's stock fell -5.9% during the 2025 US Tariff Shock. Such a loss loss requires a 6.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
WGRX has limited trading history. Below is the Consumer Staples sector ETF (XLP) in its place.
| Event | XLP | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -24.2% | -33.7% |
| % Gain to Breakeven | 31.9% | 50.9% |
| Time to Breakeven | 140 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -31.8% | -53.4% |
| % Gain to Breakeven | 46.7% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street Consumer Staples Select Sector SPDR ETF's stock fell -5.9% during the 2025 US Tariff Shock. Such a loss loss requires a 6.2% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Wellgistics Health (WGRX)
Wellgistics Health, Inc. (WGRX) is a holding company, founded in 2022, focused on building a "micro health ecosystem" through strategic acquisitions in pharmaceuticals and healthcare services. It integrates diverse businesses aimed at improving patient care and optimizing various components of the healthcare supply chain. The company recently completed acquisitions in 2024, bringing its operational subsidiaries under a unified structure.
The company's core business revolves around three main operational pillars. It operates a retail community specialty pharmacy, which directly serves patients with specialized medication needs. Additionally, it runs wholesale operations for the distribution and fulfillment of pharmaceutical medications to a network of independent pharmacies, with the goal of improving market access. Wellgistics Health also boasts a technology division that provides a novel platform for pharmaceutical technology hub and clinical services, streamlining processes and support within the industry.
Wellgistics Health serves a broad spectrum of clients and markets within the healthcare sector. Its primary customers include patients, independent pharmacies looking for efficient distribution and market access, healthcare providers, pharmaceutical manufacturers, and payors. The company's mission is to deliver unique solutions across these stakeholders, ultimately enhancing patient outcomes and providing value throughout the healthcare landscape.
AI Analysis | Feedback
1. Think of it as an integrated pharmaceutical services company, similar to a 'mini-Optum' but exclusively focused on drug distribution, specialty pharmacy, and related technology.
2. It's like a smaller, vertically integrated pharmaceutical provider that combines the drug wholesale capabilities of a McKesson with a specialty pharmacy and a technology platform for patient services.
3. Imagine an 'Amazon for specialized pharmaceutical services', providing a tech-enabled platform for drug distribution, specialty pharmacy, and patient care.
AI Analysis | Feedback
- Retail Community Specialty Pharmacy Services: Provides specialized pharmacy services to patients within the community.
- Wholesale Pharmaceutical Distribution: Focuses on the distribution and fulfillment of pharmaceutical medications to independent pharmacies.
- Pharmaceutical Technology Hub & Clinical Services Platform: Offers a novel technology platform for pharmaceutical hub and clinical services.
AI Analysis | Feedback
Wellgistics Health (WGRX) serves a diverse range of customers, encompassing both individuals and various entities within the healthcare industry. Based on the company description, its major customer categories are:
- Individuals/Patients: Through its subsidiary CSP (a retail community specialty pharmacy), Wellgistics Health directly serves patients in need of specialty medications.
- Independent Pharmacies: Its subsidiary Wellgistics LLC operates wholesale distribution and fulfillment for certain pharmaceutical medications to a network of independent pharmacies, helping them improve market access and patient outcomes.
- Other Healthcare Businesses: Through its technology division APS (a pharmaceutical technology hub), Wellgistics Health provides solutions and services to a broader range of healthcare entities, including other pharmacies, providers, pharmaceutical manufacturers, and payors.
AI Analysis | Feedback
AI Analysis | Feedback
Prashant Patel, RPh, Interim-CEO & President
Mr. Patel is an entrepreneur and registered Pharmacist with extensive experience across various facets of the pharmaceutical supply chain. He co-founded, served as Director, President, and COO of TRxADE Health, Inc., where he pioneered innovative technology for secondary distribution, reverse distribution, and logistics. Mr. Patel has founded several startups, including a Retail/Community Pharmacy, and expanded into pharmaceutical distribution and sales with a focus on pharmaceutical disposal and reverse distribution. He has also served as a consultant to various return logistics pharmaceutical companies. He was re-appointed as Interim-CEO and President of Wellgistics Health in October 2025, having previously served as a Director, Chief Strategy Officer, and Vice Chairman of the Board of Directors for the company from 2023 until August 2025. Additionally, Mr. Patel served on the board of Scienture following its acquisition of TRxADE Group, Inc. from 2014 until 2025.
Eric Sherb, Interim-CFO
Mr. Sherb is a Certified Public Accountant with 16 years of experience in accounting advisory, auditing, and mergers and acquisitions, including capital markets experience with IPOs and direct listings. He is the Founder and Owner of EMS Consulting Services. His prior experience includes roles at PwC, RBSM LLP, and CFGI, where his core expertise focused on technical advisory for complex transactions, debt/equity financing, mergers and acquisitions, auditing, and IPO readiness. Mr. Sherb was appointed Interim-CFO of Wellgistics Health in October 2025.
Dr. Shafaat Pirani, PharmD, BCGP, Chief Clinical Officer
Dr. Pirani has served as the Chief Clinical & Regulatory Compliance Officer for Bonum Health and TRxADE Health, Inc. His background also includes roles as EVP of Alliance Pharma Solutions and Director of Operations for an independent mail-order pharmacy affiliated with a Pharmacy Benefit Manager (PBM).
Srini Kalla, Chief Technology Officer
Mr. Kalla previously held positions as Vice President of IT at OptumRx (UHG) and Principal at Elevance Health, where he focused on pharmacy and PBM healthcare technology and led various technology initiatives and M&A. At Wellgistics Health, he is responsible for modernizing the company's digital and data infrastructure, advancing its AI integration strategy, compliance frameworks, and platform interoperability. His background also includes senior leadership roles at Optum Workers' Comp and Auto No-Fault.
David Saslow, Corporate Counsel
Mr. Saslow has served as General Counsel and Chief Legal Officer for Automated Retail Technologies, Chessler Holdings, McIntyre Law Firm, and GPS Industries. He advises leadership on legal, regulatory, and strategic matters, bringing experience in technology-enabled businesses, complex commercial transactions, and enterprise risk management.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
Share Issuance
- Wellgistics Health completed its Initial Public Offering (IPO) in February 2025, raising $4.0 million in gross proceeds from the sale of 888,889 shares of common stock at $4.50 per share.
- In September 2025, the company priced a public offering of 7,142,862 shares of common stock with accompanying warrants at $0.70 per share, expecting to raise approximately $5 million in gross proceeds for working capital, general corporate purposes, operating expenses, research and development, and potential acquisitions.
- As part of the Wellgistics acquisition, which closed in August 2024, 3,999,335 restricted shares valued at $15,000,000 were issued as transaction consideration in September 2025.
Outbound Investments
- Wellgistics Health acquired Wood Sage in June 2024, making it a wholly owned subsidiary and subsequently acquiring Wood Sage’s operating subsidiaries, APS and CSP.
- On August 30, 2024, Wellgistics Health completed the Wellgistics Acquisition, making Wellgistics LLC a wholly owned subsidiary, with consideration including a cash component and the issuance of 3,999,335 restricted shares valued at $15,000,000.
- In February 2026, Wellgistics Health made a strategic investment in a San Francisco-based mental health artificial intelligence company.
Capital Expenditures
- Proceeds from the February 2025 IPO were planned to be utilized for general corporate purposes, including capital expenditures.
- The company's operating costs, particularly in healthcare technology and pharmaceutical services, require significant capital expenditures.
- Capital expenditures are likely focused on enhancing technology infrastructure, such as the EinsteinRx™ AI platform and PharmacyChain™ blockchain platform, and supporting its pharmacy and wholesale distribution operations.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Wellgistics Health Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 166.68 |
| Mkt Cap | 56.1 |
| Rev LTM | 289,708 |
| Op Inc LTM | 3,624 |
| FCF LTM | 2,972 |
| FCF 3Y Avg | 2,682 |
| CFO LTM | 3,639 |
| CFO 3Y Avg | 3,245 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.0% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 4.9% |
| QoQ Delta Rev Chg LTM | 1.2% |
| Op Inc Chg LTM | 15.8% |
| Op Inc Chg 3Y Avg | 18.4% |
| Op Mgn LTM | 1.2% |
| Op Mgn 3Y Avg | 1.3% |
| QoQ Delta Op Mgn LTM | 0.0% |
| CFO/Rev LTM | 1.8% |
| CFO/Rev 3Y Avg | 1.5% |
| FCF/Rev LTM | 1.5% |
| FCF/Rev 3Y Avg | 1.3% |
Price Behavior
| Market Price | $2.71 | |
| Market Cap ($ Bil) | 0.0 | |
| Distance from 52W High | -96.9% | |
| 50 Days | 200 Days | |
| DMA Price | $3.82 | $79.45 |
| DMA Trend | down | down |
| Distance from DMA | -29.1% | -96.6% |
| 3M | 1YR | |
| Volatility | 258.6% | 265.0% |
| Downside Capture | 230.09 | 275.43 |
| Upside Capture | -218.14 | -126.49 |
| Correlation (SPY) | -0.4% | 6.8% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.30 | -1.00 | -0.34 | 0.78 | 1.40 | -0.86 |
| Up Beta | -0.89 | -1.66 | -0.84 | -0.79 | 1.37 | 1.37 |
| Down Beta | -4.40 | 4.20 | 2.96 | 3.35 | 2.73 | 2.65 |
| Up Capture | 69% | -243% | -79% | -79% | -47% | -4% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 15 | 24 | 43 | 90 | 123 |
| Down Capture | 158% | 13% | 100% | 219% | 174% | 108% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 26 | 38 | 81 | 160 | 211 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGRX | |
|---|---|---|---|---|
| WGRX | -94.2% | 264.7% | -0.23 | - |
| Sector ETF (XLP) | 6.8% | 13.8% | 0.24 | 0.0% |
| Equity (SPY) | 19.2% | 12.6% | 1.12 | 6.8% |
| Gold (GLD) | 19.6% | 28.0% | 0.63 | 6.3% |
| Commodities (DBC) | 29.7% | 19.0% | 1.24 | 3.4% |
| Real Estate (VNQ) | 15.2% | 14.0% | 0.78 | 0.9% |
| Bitcoin (BTCUSD) | -46.6% | 42.9% | -1.34 | 1.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGRX | |
|---|---|---|---|---|
| WGRX | -57.3% | 241.0% | -0.44 | - |
| Sector ETF (XLP) | 6.6% | 13.5% | 0.27 | 4.3% |
| Equity (SPY) | 12.6% | 17.1% | 0.57 | 9.7% |
| Gold (GLD) | 16.8% | 18.4% | 0.74 | 6.2% |
| Commodities (DBC) | 8.8% | 19.5% | 0.34 | 2.8% |
| Real Estate (VNQ) | 2.6% | 18.9% | 0.04 | 7.6% |
| Bitcoin (BTCUSD) | 14.0% | 53.5% | 0.44 | 2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with WGRX | |
|---|---|---|---|---|
| WGRX | -34.7% | 241.0% | -0.44 | - |
| Sector ETF (XLP) | 7.1% | 14.8% | 0.35 | 4.3% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 9.7% |
| Gold (GLD) | 10.9% | 16.1% | 0.55 | 6.2% |
| Commodities (DBC) | 7.0% | 17.9% | 0.31 | 2.8% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 7.6% |
| Bitcoin (BTCUSD) | 57.9% | 66.2% | 0.98 | 2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/23/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/19/2026 | -23.2% | -62.4% | -59.6% |
| 11/20/2025 | 2.4% | 14.4% | -12.4% |
| 8/22/2025 | 73.5% | 30.2% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 1 |
| # Negative | 1 | 1 | 2 |
| Median Positive | 37.9% | 22.3% | 7.9% |
| Median Negative | -23.2% | -62.4% | -36.0% |
| Max Positive | 73.5% | 30.2% | 7.9% |
| Max Negative | -23.2% | -62.4% | -59.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/19/2026 | -23.2% | -62.4% | -59.6% |
| 11/20/2025 | 2.4% | 14.4% | -12.4% |
| 8/22/2025 | 73.5% | 30.2% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 2 | 2 | 1 |
| # Negative | 1 | 1 | 2 |
| Median Positive | 37.9% | 22.3% | 7.9% |
| Median Negative | -23.2% | -62.4% | -36.0% |
| Max Positive | 73.5% | 30.2% | 7.9% |
| Max Negative | -23.2% | -62.4% | -59.6% |
Industry Resources
| Consumer Staples Resources |
| FoodNavigator |
| Consumer Goods Technology (CGT) |
| Beverage Digest |
| Drug Retail Resources |
| Drug Store News |
| Chain Drug Review |
| Pharmacy Times |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.